沙利度胺联合XELOX方案治疗晚期结直肠癌42例

目的观察沙利度胺联合XELOX方案对晚期结直肠癌的疗效及不良反应。方法 42例晚期结直肠癌患者口服沙利度胺200mg/d,服用1～10d;同时采用奥沙利铂130mg/m^2,1d,静脉滴注2h;卡培他滨2000mg/（m^2·d）,分早晚2次,餐后30min口服,1～14d。21d为1个周期,2个周期后评价疗效。近期疗效按RECIST标准评价。结果 42例中完全缓解2例（4.76%）,部分缓解20例（47.62%）,疾病稳定10例（23.81%）,进展10例（23.81%）;有效率为52.38%;中位生存期为13.6月;疾病进展时间为7.2月。主要不良反应为神经系统毒性、白细胞降低和手足综合征。结论沙利度胺联合XELOX方案治疗晚期结直肠癌疗效肯定,安全性较好。

Clinical Study of XELOX plus Thalidomide for Treating Advanced Colorectal Cancers in 42 Cases

Objective To observe the therapeutic effects and adverse reactions of thalidomide combined with capecitabine and oxaliplatin（XELOX） in the treatment of advanced colorectal cancers.Methods Forty-two patients with advanced colorectal cancers received thalidomide 200 mg /（m^2 · d）,on 1-10 d] and the chemotherapeutic regimen oxaliplatin 130 mg /m2 by intravenous drip for 2 h on 1 d,capecitabine 2 000 mg /m^2,taking orally at 30 min after meal,twice a day,on 1-14 d,3 weeks as one circle.The efficacy was evaluated after 2 circles.Results Among 42 cases,2 cases（4.76%） achieved complete response（CR）,20 cases（47.62%） partial response（PR）,10 cases（23.81%） stable disease and 10 cases（23.81%） progression disease（PD）.The overall response rate was 52.38%.MST was 13.6 months and TTP was 7.2 months.The major toxicity included neurotoxicity,leucopenia and hand-foot syndrome.Conclusion The regimen of thalidomide combined XELOX is effective and tolerable in the treatment of advanced colorectal cancers.